New insider activity at Abeona Therapeutics ( (ABEO) ) has taken place on January 21, 2026.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Director Mark Alvino of Abeona Therapeutics has recently sold 13,500 shares of the company’s stock in a transaction valued at $70,470, signaling a notable insider move that may draw the attention of investors tracking management’s trading activity.
Spark’s Take on ABEO Stock
According to Spark, TipRanks’ AI Analyst, ABEO is a Neutral.
The score is held back mainly by weak operating performance and persistent cash burn despite a stronger balance sheet. Offsetting this, the latest earnings call reflected solid commercial and reimbursement progress for ZivaSkin, and technicals show modest near-term momentum, while valuation appears optically low but is tempered by earnings-quality concerns.
To see Spark’s full report on ABEO stock, click here.
More about Abeona Therapeutics
YTD Price Performance: 0.76%
Average Trading Volume: 1,774,807
Technical Sentiment Signal: Sell
Current Market Cap: $284.5M